Stocks Overview

LAST PRICE
0.9055
TODAY'S CHANGE (%)
Trending Up0.0119 (1.3317%)

Bid / Lots
0.9000/ 1
Ask / Lots
0.9100/ 2
Open / Previous Close
0.8913 / 0.8936
Day Range
Low 0.8660
High 0.9282
52 Week Range
Low 0.8000
High 6.0000
Volume
744,188
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 0.8936
Time	Volume	TPST
09:32 ET	12616	0.8845
09:33 ET	9241	0.8845
09:35 ET	6921	0.88
09:37 ET	3000	0.8797
09:39 ET	10112	0.8669
09:42 ET	1449	0.8669
09:46 ET	10622	0.8748
09:48 ET	15572	0.8733
09:50 ET	1600	0.87
09:51 ET	7178	0.8733
09:53 ET	400	0.8735
09:55 ET	100	0.8795
09:57 ET	10315	0.889
10:00 ET	2699	0.9
10:02 ET	8277	0.8997
10:04 ET	1200	0.8997
10:06 ET	300	0.8901
10:08 ET	200	0.8988
10:09 ET	2200	0.8979
10:11 ET	200	0.8973
10:13 ET	7217	0.8869
10:15 ET	2088	0.89185
10:18 ET	12300	0.89
10:20 ET	1048	0.8978
10:22 ET	600	0.898
10:24 ET	600	0.898
10:26 ET	12603	0.89771
10:27 ET	1400	0.9085
10:29 ET	400	0.9083
10:31 ET	1000	0.9067
10:33 ET	2598	0.90025
10:36 ET	100	0.9053
10:38 ET	10600	0.90025
10:40 ET	800	0.9057
10:42 ET	400	0.9055
10:44 ET	611	0.9081
10:45 ET	300	0.9087
10:47 ET	400	0.9087
10:49 ET	500	0.9087
10:51 ET	535	0.908499
10:54 ET	1947	0.905
10:56 ET	980	0.905
10:58 ET	3200	0.905
11:00 ET	1703	0.905
11:02 ET	300	0.905
11:03 ET	700	0.9087
11:05 ET	4950	0.9047
11:07 ET	300	0.9025
11:09 ET	1311	0.9025
11:12 ET	100	0.902
11:14 ET	9830	0.8985
11:16 ET	555	0.8933
11:18 ET	112	0.8869
11:20 ET	2600	0.9
11:21 ET	9370	0.905
11:23 ET	3382	0.9001
11:25 ET	939	0.909
11:27 ET	4408	0.9094
11:30 ET	4200	0.909
11:32 ET	410	0.908999
11:34 ET	481	0.9065
11:36 ET	1200	0.9037
11:38 ET	3885	0.9039
11:39 ET	700	0.9088
11:41 ET	3388	0.907
11:43 ET	559	0.907
11:45 ET	200	0.907
11:48 ET	400	0.9075
11:50 ET	100	0.9075
11:52 ET	200	0.9063
11:54 ET	450	0.9003
11:56 ET	1793	0.9077
11:57 ET	400	0.907
11:59 ET	3149	0.9039
12:01 ET	3138	0.9074
12:03 ET	1600	0.90495
12:06 ET	1316	0.9048
12:08 ET	3198	0.9022
12:10 ET	400	0.9075
12:12 ET	100	0.906
12:14 ET	400	0.9075
12:15 ET	100	0.9075
12:17 ET	200	0.9075
12:19 ET	475	0.9088
12:21 ET	350	0.9088
12:26 ET	480	0.9065
12:28 ET	2747	0.909
12:30 ET	46252	0.907906
12:32 ET	500	0.92
12:33 ET	3200	0.9133
12:35 ET	11251	0.92
12:37 ET	1310	0.917134
12:39 ET	63079	0.925
12:42 ET	23765	0.9217
12:44 ET	3315	0.9159
12:46 ET	714	0.921699
12:48 ET	2665	0.92
12:50 ET	5056	0.911
12:51 ET	4800	0.911
12:53 ET	381	0.92
12:55 ET	20731	0.92
12:57 ET	2000	0.92
01:00 ET	3670	0.911
01:02 ET	400	0.92
01:04 ET	1791	0.92
01:06 ET	508	0.92
01:08 ET	2646	0.92
01:09 ET	850	0.92
01:11 ET	1050	0.92
01:13 ET	5466	0.92
01:15 ET	1780	0.92
01:18 ET	9526	0.92
01:20 ET	662	0.92
01:22 ET	900	0.92
01:24 ET	1500	0.91525
01:26 ET	781	0.912961
01:27 ET	300	0.9155
01:29 ET	200	0.92
01:31 ET	100	0.92
01:33 ET	219	0.9156
01:36 ET	9389	0.92
01:38 ET	1500	0.92
01:40 ET	750	0.92035
01:42 ET	133	0.9227
01:44 ET	10518	0.9179
01:45 ET	2713	0.91445
01:47 ET	100	0.911
01:49 ET	300	0.9144
01:51 ET	2174	0.9142
01:54 ET	3908	0.9103
01:58 ET	200	0.9154
02:00 ET	300	0.9103
02:02 ET	200	0.9156
02:03 ET	100	0.9155
02:05 ET	200	0.9156
02:07 ET	15694	0.90505
02:09 ET	300	0.9099
02:14 ET	200	0.9001
02:16 ET	200	0.909499
02:18 ET	100	0.9096
02:20 ET	100	0.9096
02:21 ET	2308	0.9079
02:23 ET	200	0.9099
02:25 ET	200	0.9075
02:27 ET	200	0.9099
02:30 ET	1510	0.9099
02:32 ET	1100	0.9075
02:34 ET	9018	0.905391
02:38 ET	500	0.902551
02:39 ET	665	0.905
02:41 ET	400	0.9062
02:43 ET	1550	0.9075
02:45 ET	100	0.9075
02:48 ET	200	0.9099
02:50 ET	100	0.9099
02:54 ET	910	0.9099
02:56 ET	100	0.9079
02:57 ET	511	0.9099
02:59 ET	400	0.9099
03:01 ET	200	0.91
03:08 ET	500	0.9154
03:10 ET	100	0.9117
03:12 ET	600	0.9117
03:14 ET	400	0.9117
03:15 ET	287	0.9117
03:17 ET	300	0.91175
03:19 ET	911	0.9101
03:21 ET	715	0.9101
03:24 ET	2500	0.9154
03:26 ET	100	0.91
03:28 ET	11284	0.9102
03:30 ET	1600	0.9074
03:32 ET	3033	0.9049
03:33 ET	100	0.9102
03:35 ET	300	0.91
03:37 ET	400	0.9102
03:42 ET	26825	0.9144
03:44 ET	2246	0.9074
03:46 ET	1500	0.9096
03:48 ET	440	0.91
03:50 ET	13936	0.9063
03:51 ET	12721	0.91
03:53 ET	2972	0.9092
03:55 ET	815	0.904101
03:57 ET	8649	0.90702
04:00 ET	24918	0.9055

Data delayed at least 15 minutes.

Nov 13, 2024
- DJ Tempest Therapeutics Is Maintained at Overweight by Piper Sandler, from 12:00PM ET on Wednesday Nov 13, 2024 by Dow Jones
  12:00PM ET on Wednesday Nov 13, 2024 by Dow Jones
- DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co., from 7:35AM ET on Wednesday Nov 13, 2024 by Dow Jones
  7:35AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
- Press Release: Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones
- Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones
- Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesTPST Tempest Therapeutics Inc	22.5M	-0.6x	---
United StatesCLCS Cell Source Inc	22.3M	-3.5x	---
United StatesFBRX Forte Biosciences Inc	22.8M	-0.8x	---
United StatesAEON Aeon Biopharma Inc	22.1M	-0.1x	---
United StatesXTLB X T L Biopharmaceuticals Ltd	21.8M	-5.7x	---
United StatesCOCP Cocrystal Pharma Inc	21.9M	-1.2x	---
As of 2024-11-22

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Contact Information

Headquarters: 2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE, CA, United States 94005
Phone: 415-798-8589
Fax: 302-655-5049

Executives

Independent Chairman of the Board: Michael Raab
President, Chief Executive Officer, Director: Stephen Brady
Executive Vice President, Chief Medical Officer: Samuel Whiting
Vice President - Strategy and Finance, Corporate Secretary: Nicholas Maestas
Vice President - Regulatory Affairs: Sheldon Mullins

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$22.5M
Revenue (TTM)	$0.00
Shares Outstanding	25.2M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	-1.78
EPS	$-1.57
Book Value	$1.21
P/E Ratio	-0.6x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Tempest Therapeutics Inc
NASDAQ:TPSTUnited States

Search Criteria

Charts

Recent News

Nov 13, 2024

DJ Tempest Therapeutics Is Maintained at Overweight by Piper Sandler, from 12:00PM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co., from 7:35AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

Press Release: Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:21PM ET on Tuesday Nov 12, 2024 by Dow Jones

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar